Werner Lanthaler - Evotec SE President of the Management Board, CEO

EVOTF Stock  USD 13.83  0.00  0.00%   

CEO

Dr. Werner Lanthaler has served as Chief Executive Officer, Member of the Management Board at Evotec AG since 2015. He was President of the Management Board at Evotec AG from March 6, 2009 to 2015. Prior to joining the Company, Dr. Lanthaler had worked at Intercell AG since 2000, where he acted as Chief Financial Officer. Before that, he served as Director of the Federation of Austrian Industry and as Senior Management Consultant at the consulting firm McKinsey Company. In April 2014, Dr. Werner Lanthaler became a member of the Supervisory Board of arGENX and in October 2015, he became a member of the Supervisory Board of Topas Therapeutics GmbH. He holds a doctorate in economics from Universitaet Wien and earned his Master degree from Harvard University, and holds a degree in Psychology. since 2015.
Age 49
Tenure 9 years
Phone49 40 560 81 0
Webhttps://www.evotec.com

Evotec SE Management Efficiency

Evotec SE's management efficiency ratios could be used to measure how well Evotec SE manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 326.34 M in total debt with debt to equity ratio (D/E) of 0.38, which is about average as compared to similar companies. Evotec SE has a current ratio of 3.5, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Evotec SE until it has trouble settling it off, either with new capital or with free cash flow. So, Evotec SE's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evotec SE sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evotec to invest in growth at high rates of return. When we think about Evotec SE's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 1 records

CEO Age

Anre WilliamsAmerican Express
58
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. EVOTEC SE operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 4521 people. Evotec SE [EVOTF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Evotec SE Leadership Team

Elected by the shareholders, the Evotec SE's board of directors comprises two types of representatives: Evotec SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evotec. The board's role is to monitor Evotec SE's management team and ensure that shareholders' interests are well served. Evotec SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evotec SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
Matthias Evers, Chief Board
Werner Lanthaler, President of the Management Board, CEO
Claus Braestrup, Member of the Supervisory Board
Michael Shalmi, Member of the Supervisory Board
Monika Conradt, Global HR
Christian Dargel, EVP Compliance
Mario Polywka, COO and Member of Management Board
Anja Bosler, Principal Accounting
Mary Tanner, Member of the Supervisory Board
Volker Braun, VP ESG
Roland Oetker, Deputy Chairman of the Supervisory Board
Andreas Pinkwart, Member of the Supervisory Board
Paul Herrling, Member of the Supervisory Board
Colin Bond, CFO and Member of Management Board
Cord Dohrmann, Chief Scientific Officer and Member of Management Board
Iris LoewFriedrich, Member of the Supervisory Board
Bernd Hirsch, Member of the Supervisory Board
Enno Spillner, CFO, Member of the Management Board
Elaine Sullivan, Member of the Supervisory Board
Gabriele Hansen, Vice President Corporate Communications & Investor Relations
MBA MBA, Chairman CEO
Craig Johnstone, COO, Member of the Management Board
Wolfgang Plischke, Chairman of the Supervisory Board

Evotec Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Evotec SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Evotec SE

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evotec SE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evotec SE will appreciate offsetting losses from the drop in the long position's value.

Moving against Evotec Pink Sheet

  0.81TEVA Teva PharmaceuticalPairCorr
  0.79MKKGY Merck KGaA ADRPairCorr
  0.78MKGAF MERCK KommanditgesellsPairCorr
  0.74MDH MDH Acquisition CorpPairCorr
  0.73SCSC ScanSource Financial Report 14th of May 2024 PairCorr
The ability to find closely correlated positions to Evotec SE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evotec SE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evotec SE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evotec SE to buy it.
The correlation of Evotec SE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evotec SE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evotec SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evotec SE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Complementary Tools for Evotec Pink Sheet analysis

When running Evotec SE's price analysis, check to measure Evotec SE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evotec SE is operating at the current time. Most of Evotec SE's value examination focuses on studying past and present price action to predict the probability of Evotec SE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evotec SE's price. Additionally, you may evaluate how the addition of Evotec SE to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stocks Directory
Find actively traded stocks across global markets
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Fundamental Analysis
View fundamental data based on most recent published financial statements
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.